1 Monster Stock in the Making to Buy and Hold
This biotech company was relatively unknown a few years ago.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT - Summit Therapeutics ( NASDAQ:SMMT )
NEW YORK, Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ( "Summit" or the "Company" ) SMMT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Nvidia Meets Palantir, Rocket Lab On The '10-Bagger' Legends List - NVIDIA ( NASDAQ:NVDA )
Ten stocks in the large-cap Russell 1000 index have achieved at least 1,000% returns since the October 2022 bull market bottom, showcasing the power and volatility of high-growth companies in a rapidly recovering market environment. NVDA stock is up 36% this year. See the real-time chart here
Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?
FDA clears MRK's Keytruda Qlex, a subcutaneous option that promises faster treatment and new patent protection amid looming headwinds.
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Biohaven ( NYSE:BHVN ) , Avient ( NYSE:AVNT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Opendoor? No Meme Stocks, Ring The Register: Jim Cramer - Lumentum Holdings ( NASDAQ:LITE ) , Hubbell ( NYSE:HUBB )
"We're going to have to move on," Cramer on Summit Therapeutics. See the trading strategy with a perfect track record in 2025 [currently 34-0] → On CNBC's "Mad Money Lightning Round," Jim Cramer recommended ringing the register on Opendoor Technologies Inc. OPEN. "We don't want to be in a meme ...
Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?
Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.
CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm - Summit Therapeutics ( NASDAQ:SMMT )
LOS ANGELES, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- The original press release, distributed Tuesday, September 9, 2025, incorrectly stated that a lawsuit was filed against Summit Therapeutics, in the headline and body of the release.
Summit Therapeutics Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 24, 2025 Deadline to file Lead Plaintiff Motion. - Summit Therapeutics ( NASDAQ:SMMT )
Investors can contact the law firm at no cost to learn more about recovering their losses
SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study
Summit Therapeutics plunges 25% after its HARMONi study shows sharp regional differences in lung cancer trial outcomes.
Top 3 Health Care Stocks You'll Regret Missing In Q3 - CERo Therapeutics Hldgs ( NASDAQ:CERO ) , Lunai Bioworks ( NASDAQ:RENB )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
Is Summit Therapeutics a Buy, Sell, or Hold Now?
Western results for ivonescimab aren't lining up with the huge survival benefit measured in China.
Gold Moves Higher; Robinhood Shares Jump - Robinhood Markets ( NASDAQ:HOOD ) , Banco Macro ( NYSE:BMA )
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining over 100 points on Monday. The Dow traded up 0.01% to 45,404.20 while the NASDAQ rose 0.67% to 21,845.34. The S&P 500 also rose, gaining, 0.25% to 6,497.56. Information technology shares jumped by 1.1% on ...
Why Is Summit Therapeutics Stock Sinking Monday? - Summit Therapeutics ( NASDAQ:SMMT )
Median overall survival for ivonescimab was 17.0 months vs. 14.0 months for placebo in Western patients. Ivonescimab plus chemo cut progression risk by 33% in Western patients and 45% in Chinese patients. Get the strategy to turn September's volatility into 10x trades → Summit Therapeutics Inc.
Why Is Summit Therapeutics Stock Sinking Monday? - Summit Therapeutics ( NASDAQ:SMMT )
Median overall survival for ivonescimab was 17.0 months vs. 14.0 months for placebo in Western patients. Ivonescimab plus chemo cut progression risk by 33% in Western patients and 45% in Chinese patients. Get the strategy to turn September's volatility into 10x trades → Summit Therapeutics Inc.
New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session - CNFinance Hldgs ( NYSE:CNF ) , Empresa Distribuidora y ( NYSE:EDN )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday. Shares of New Fortress Energy Inc. NFE fell sharply in pre-market trading following second-quarter results.
Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket - CDT Equity ( NASDAQ:CDT ) , Acrivon Therapeutics ( NASDAQ:ACRV )
Shares of Robinhood Markets, Inc. HOOD rose sharply in pre-market trading. S&P Dow Jones Indices announced a sweeping update to its benchmarks late Friday, unveiling new additions to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600. Robinhood will replace Caesars Entertainment Inc.
3 No-Brainer Stocks to Buy Right Now
Investing in these pharmaceutical stocks is an easy decision.
Summit, Akeso Lung Cancer Drug Rivals Merck's Keytruda - Summit Therapeutics ( NASDAQ:SMMT )
Ivonescimab meets the overall survival endpoint in EGFR-mutant NSCLC, showing a strong survival benefit. HC Wainwright raises Summit's price target to $50, citing 85% approval odds. Tonight: Get a FREE TRADE, built by the seasonal trading strategy that's beating the S&P 500 by 6X this year.
JM Smucker, Baidu And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - BitMine Immersion Techs ( AMEX:BMNR ) , Baidu ( NASDAQ:BIDU )
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Wednesday. Shares of The J. M. Smucker Company SJM fell sharply in pre-market trading after the company reported weaker-than-expected second-quarter results.
This Is What Whales Are Betting On Summit Therapeutics - Summit Therapeutics ( NASDAQ:SMMT )
Whales with a lot of money to spend have taken a noticeably bearish stance on Summit Therapeutics. Looking at options history for Summit Therapeutics SMMT we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with ...
What's Going On With BeOne Medicines Stock Monday? - Royalty Pharma ( NASDAQ:RPRX ) , BeOne Medicines ( NASDAQ:ONC ) , Amgen ( NASDAQ:AMGN )
BeOne to sell Imdelltra royalties for $885 million upfront, plus $65 million option within a year. Royalty deal excludes China, with profit-sharing on sales above $1.5 billion annually. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here → BeOne Medicines ...
Can Keytruda Sustain Merck's Growth Through the Rest of 2025?
MRK banks on Keytruda's soaring sales and new oncology strategies to fuel 2025 growth, even as competition and patent loss loom.
3 Fantastic Growth Stocks to Buy in August
Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus
Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.
Merck Stock Down 4% Since Q2 Results: How to Play the Stock
Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.
2 Beaten-Down Stocks With Incredible Upside Potential
Getting in on the ground floor with these companies might lead to superior returns.
Pandemic darlings Moderna, BioNTech are now on two different paths
The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find themselves on different paths.
Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?
MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth.
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results
Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, long-term investors should have a balanced approach to potentially positive data readouts.
This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich
Three years ago, Summit Therapeutics ( NASDAQ: SMMT ) was a little-known small-cap biotech that few investors with an average tolerance for risk would have bothered to pay attention to at the time. However, the company's shares have skyrocketed by more than 2,000% since then.As is often the case ...
3 Monster Stocks in the Making to Buy Right Now
Where can you find the next monster stocks? Check out the biotech space. It's not easy, but investors can sometimes find highly promising biotech stocks that are only in their early innings.Three Motley Fool contributors think they've identified monster stocks in the making.
Johnson & Johnson Raises FY25 Forecast, Joins Rigetti Computing, Unity Software, Brighthouse Financial And Other Big Stocks Moving Higher On Wednesday - BitMine Immersion Techs ( AMEX:BMNR ) , Brighthouse Finl ( NASDAQ:BHF )
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Wednesday. Shares of Johnson & Johnson JNJ rose sharply during Wednesday's session after the company raised its FY2025 earnings guidance.
Elevance to Report Q2 Earnings: Will Rising Costs Pressure Profits?
ELV's second-quarter earnings may face pressure as rising costs and lower Medicaid memberships offset strong revenue gains.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT - Summit Therapeutics ( NASDAQ:SMMT )
NEW YORK, July 14, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ( "Summit" or the "Company" ) SMMT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Intuit ( NASDAQ:INTU ) , AstraZeneca ( NASDAQ:AZN )
The Benzinga Stock Whisper Index highlights five stocks each week seeing more interest from readers than normal. Several stocks on the list could be impacted by the new "Big Beautiful Bill." Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?
MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.
2 Top Stocks Down 16% and 17% This Year to Buy and Hold
Most people love a bargain. investors do too. Purchasing shares of companies that can perform well over long periods is already pretty exciting, but it's even more so when they can be scooped up from the discount bin.
Why Is AbbVie Stock Trading Higher On Thursday? - AstraZeneca ( NASDAQ:AZN ) , AbbVie ( NYSE:ABBV )
IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. ABBV, on Thursday, announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT protein platform, for oncology and ...
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug - Merck & Co ( NYSE:MRK ) , Verona Pharma ( NASDAQ:VRNA )
Merck will pay $107 per ADS in a $10-billion acquisition of Verona Pharma. FDA approved Verona's Ohtuvayre in June 2024 as a novel COPD maintenance therapy. Get daily-updated rankings across momentum, growth, value, trends, and quality to spot the strongest stocks in any market. Merck & Co. Inc.
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
2 Soaring Stocks With More Upside Potential to Buy and Hold
Is it worth it to buy a stock after it experiences significant market gains? The answer is, it depends. Some companies don't have much growth fuel left in the tank after a nice run, while others still boast significant upside potential after juicy gains.
Why AstraZeneca Stock Got Thumped on Thursday
AstraZeneca ( NASDAQ: AZN ) might soon be on the hook for an eventual 11-figure payout, and investors weren't all that comfortable with this. A Bloomberg article published Thursday morning said that the company is pursuing what might end up being an expensive partnership with a biotech.A cautious ...
Why Summit Therapeutics Stock Soared 8% Higher Today
One day before the July Fourth holiday, the stock of clinical-stage biotech Summit Therapeutics ( NASDAQ: SMMT ) exploded like a powerful fireworks display. Shares of the cancer-focused company leaped by 8%, on a media report that a well-known peer was interested in a licensing deal.
AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment - AstraZeneca ( NASDAQ:AZN ) , Summit Therapeutics ( NASDAQ:SMMT )
AstraZeneca may pay up to $15 billion for rights to Summit's lung cancer drug, ivonescimab. Bob Duggan owns nearly 75% of Summit, which is valued at $17.4 billion. From tariffs to inflation, macro risks are rising-Matt Maley reveals how he's trading it all, live this Wednesday July 9 at 6 PM ET.
Wall Street Analysts Believe Summit Therapeutics ( SMMT ) Could Rally 63.02%: Here's is How to Trade
The mean of analysts' price targets for Summit Therapeutics (SMMT) points to a 63% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS ( ON ) Inhibitors with Ivonescimab in RAS Mutant Tumors - Summit Therapeutics ( NASDAQ:SMMT ) , Revolution Medicines ( NASDAQ:RVMD )
REDWOOD CITY, Calif. and MIAMI, June 30, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. RVMD, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics, Inc.
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS ( ON ) Inhibitors with Ivonescimab in RAS Mutant Tumors
REDWOOD CITY, Calif. and MIAMI, June 30, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( Nasdaq: RVMD ) , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics, Inc. ( Nasdaq: SMMT ) , a biopharmaceutical ...
2 Stocks Too Cheap to Ignore at These Prices
The S&P 500 flirted with bear-market territory earlier this year. Although it has mostly recovered, plenty of companies are still dealing with issues that have led to poor performances. Some of them have excellent prospects, though, making their current situations a great opportunity for ...
Merck Moves Past 50-Day Average: How to Play MRK Stock Now
MRK breaks above its 50-day average but near-term headwinds and weak China sales challenge the bullish case.
